Additionally , 9 ( 52.9 % ) out of 17 patients in the topiramate group and 2 ( 12.5 % ) out of 16 patients in the placebo group showed more than 34 % decline in YBOC score ( x2 = 6.0 , df = 1 , P < 0.01 ) .